Eurofins Scientific (ERF) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue grew 6.9% year-over-year to €1,767m, driven by organic growth, acquisitions, and strong performance in food, environmental, and biopharma testing, despite fewer public working days and adverse weather in the U.S.

• Organic revenue growth was 3.9% (2.6% excluding public working day adjustment), with contributions from start-ups, new labs, and resilience in core testing services.

• Eleven acquisitions closed in Q1 2025, including SYNLAB's clinical diagnostics in Spain, adding over €160m in FY 2024 pro-forma revenues; 5 new start-up labs and 14 blood collection points established.

• CEO emphasized resilience amid macroeconomic and geopolitical uncertainties, with non-cyclical demand and operational improvements supporting growth.

• Agroscience remains soft with no near-term recovery expected, but the overall market outlook is positive due to the resilience of core testing services.

Financial highlights

• Q1 2025 reported revenues: €1,767m, up from €1,653m in Q1 2024, with organic growth of 3.9% and FX tailwind of 1.2%.

• Start-ups contributed 1.0% to organic growth, with 5 new labs and 14 blood collection points established.

• Share buybacks: 4.78m shares repurchased; 10.8m shares cancelled as of April 2025.

• Proposed dividend: €0.60 per share, subject to AGM approval.

• Clinical diagnostics and biopharma segments affected by base effects, but capacity additions are expected to drive future growth and profitability.

Outlook and guidance

• FY 2025 and FY 2027 objectives confirmed: mid-single-digit organic growth, €250m average annual acquisition revenue, improved Adj. EBITDA margin above FY 2024's 22.3%, and cash conversion above 50%.

• No changes to previously published 2024 objectives; management remains optimistic about achieving acquisition and growth targets.

• Second half of the year expected to benefit from easier comparables, especially in Q4, supporting a stronger performance.

• Tariffs under discussion in Europe not expected to materially impact cost structure.

• FX volatility remains a challenge, with no attempt to forecast or hedge long-term currency impacts.